USA Today (6/16, Alltucker) reports Roche’s Alzheimer’s disease “drug crenezumab did not slow or prevent cognitive decline in a long-running study of Colombian families who carried” the paisa mutation “that put them at near certain risk to develop the” disease, according to findings from the 252-patient study. The study tested whether the drug “could slow or halt the disease if participants took the medication before memory or thinking problems surfaced,” but it “did not demonstrate a significant benefit in tests measuring cognitive abilities or memory function…Roche said Thursday in a news release.”
Reuters (6/16, Koltrowitz, Grover) reports this “failure marks another blow to the hypothesis that targeting toxic protein plaque known as beta amyloid in the brain is a viable approach to arresting the progression of Alzheimer’s disease.”
Related Links:
— “Alzheimer’s drug fails to slow or halt disease with early treatment “Ken Alltucker, USA TODAY, June 16, 2022